|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Gfi1.1 regulates hematopoietic lineage differentiation during zebrafish embryogenesis显示文摘(GFI1 ) 生长因素独立 1 为成年造血的干细胞(HSC ) 的哺乳动物的淋巴细胞和 neutrophils 和维护的成熟是重要的。在胚胎的造血作用的 GFI1 的角色是很好描绘的更少。通过一幅 enhancer 陷井屏幕和生物信息学分析,我们识别了 Gfi1 (命名 gfi1.1 ) 的一个斑马鱼相当或相同的事物并且在胚胎发育期间分析了它的功能。内长的 gfi1.1 基因和在它的 genomic 地点附近插入的 GFP 记者基因的表示在斑马鱼胚胎的造血的房间被检测。Morpholino (瞬间) gfi1.1 击倒 scl, lmo2, c-myb, mpo, rag1, gata1 和血红素高山的减少的表示哈 embryonic-1 (hbae1 ) ,以及胚胎的血红素的全部的数量,而是 pu.1 和 l-plastin 的增加的表示。在一样的条件下面,瞬间注射没影响涉及的标记脉管并且专业版肾的开发。相反地,在经由信使 rna 的 gfi1.1 的表示上,注射提高了 gata1 的表示,但是禁止了 pu.1 的表示。这些调查结果建议 Gfi1.1 在调整胚胎的 erythroid 和 myeloid 系决心的平衡起一个关键作用,并且也在斑马鱼期间为淋巴细胞和 granulocytes 的区别被要求胚胎开始。 | Wei Wei Lu Wen Peng Huang Zheng Zhang Yuanyuan Chen An Xiao Haigen Huang Zuoyan Zhu Bo Zhang Shuo Lin | 2008 | Cell Research2008，18，6： | 3 |
| 2 | First principles study of CuAlO_2 doping with S显示文摘We study the electronic properties of CuAlO2 doped with S by the first principles calculations and find that the band gap of CuAlO2 is reduced after the doping.At the same time,the effective masses are also reduced and the density of states could cross the Fermi level.These results show that the conductivity of CuAlO2 could be enhanced by doping the impurities of S,which needs to be further studied. | GAO HaiGen 1,ZHOU Jian 1,2* & LU MingHui 1 1 National Laboratory of Solid State Microstructures and Department of Materials Science and Engineering,Nanjing University,Nanjing 210093,China 2 Group of Computational Condensed Matter Physics,National Laboratory of Solid State Microstructures and Department of Physics,Nanjing University,Nanjing 210093,China | 2010 | Science China(Physics,Mechanics & Astronomy)2010，53，7： | 2 |
| 3 | First-principles study of the IVA group atoms adsorption on graphene 显示文摘 | Haigen Gao Jian Zhou Minghui Lu | 2010 | Journal of applied physics2010，107，11： | 1 |
| 4 | Discovery of small-molecule activators of nicotinamide phosphoribosyltransferase(NAMPT)and their preclinical neuroprotective activity显示文摘The decline of nicotinamide adenine dinucleotide(NAD)occurs in a variety of human pathologies including neurodegeneration.NAD-boosting agents can provide neuroprotective benefits.Here,we report the discovery and development of a class of potent activators(NATs)of nicotinamide phosphoribosyltransferase(NAMPT),the rate-limiting enzyme in the NAD salvage pathway.We obtained the crystal structure of NAMPT in complex with the NAT,which defined the allosteric action of NAT near the enzyme active site.The optimization of NAT further revealed the critical role of K189 residue in boosting NAMPT activity.NATs effectively increased intracellular levels of NAD and induced subsequent metabolic and transcriptional reprogramming.Importantly,NATs exhibited strong neuroprotective efficacy in a mouse model of chemotherapy-induced peripheral neuropathy(CIPN)without any overt toxicity.These findings demonstrate the potential of NATs in the treatment of neurodegenerative diseases or conditions associated with NAD level decline. | Hong Yao Minghui Liu Leibo Wang Yumeng Zu Chou Wu Chenyu Li Ruoxi Zhang Haigen Lu Feifei Li Shuang Xi Shuangquan Chen Xuanyu Gu Tianya Liu Jie Cai Shirong Wang Maojun Yang Guo-Gang Xing Wei Xiong Lan Hua Yefeng Tang Gelin Wang | 2022 | Cell Research2022，32，6： | 0 |
| 5 | Evolution and development of potent monobactam sulfonate candidate IMBZ18g as a dual inhibitor against MDR Gram-negative bacteria producing ESBLs显示文摘A series of new monobactam sulfonates is continuously synthesized and evaluated for their antimicrobial efficacies against Gram-negative bacteria.Compound 33a(IMBZ18G)is highly effective in vitro and in vivo against clinically intractable multi-drug-resistant(MDR)Gram-negative strains,with a highly druglike nature.The checkerboard assay reveals its significant synergistic effect withβ-lactamase inhibitor avibactam,and the MIC values against MDR enterobacteria were reduced up to 4—512folds.X-ray co-crystal and chemoproteomic assays indicate that the anti-MDR bacteria effect of 33a results from the dual inhibition of the common PBP3 and some class A and Cβ-lactamases.Accordingly,preclinical studies of 33a alone and 33a-avibactam combination as potential innovative candidates are actively going on,in the treatment ofβ-lactamase-producing MDR Gram-negative bacterial infections. | Zhiwen Li Zhihao Guo Xi Lu Xican Ma Xiukun Wang Rui Zhang Xinxin Hu Yanxiang Wang Jing Pang Tianyun Fan Yonghua Liu Sheng Tang Haigen Fu Jingpu Zhang Yinghong Li Xuefu You Danqing Song | 2023 | Acta Pharmaceutica Sinica B2023，13，7： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员